Vizgen

Ultivue recently merged with Vizgen to lead the next frontier of innovation in spatial biology and multi-omics. Through its pioneering MERFISH technology and MERSCOPE® Platform for in situ single-cell spatial genomics and its high-fidelity InSituPlex® assays and AI-driven STARVUE™ spatial image analysis technology, Vizgen delivers unmatched tools that enable researchers to uncover deep insights into human biology and achieve breakthroughs in understanding mechanisms of complex diseases. Vizgen’s technology delivers high-confidence, quantitative data with exceptional accuracy, robustness, sensitivity and deep insights that power foundational and clinical research. Named the #1 private spatial biology company of 2024 by Genetic Engineering & Biotechnology News, Vizgen is headquartered in Cambridge, Massachusetts.